X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Roche will build its portfolio by adding Carmot’s pipeline of GLP-1/GIP receptor agonist, including CT-388, CT-996 and CT-868 which are being evaluated for the treatment of metabolic diseases including obesity and diabetes.
Lead Product(s): CT-388
Therapeutic Area: Endocrinology Product Name: CT-388
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: $3,100.0 million Upfront Cash: $2,700.0 million
Deal Type: Acquisition January 29, 2024
Details:
Through the acquisition, Roche will build its portfolio by adding Carmot’s pipeline of GLP-1/GIP receptor agonist, including CT-388, CT-996 and CT-868 which are being evaluated for the treatment of metabolic diseases including obesity and diabetes.
Lead Product(s): CT-388
Therapeutic Area: Nutrition and Weight Loss Product Name: CT-388
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: $3,100.0 million Upfront Cash: $2,700.0 million
Deal Type: Acquisition December 04, 2023
Details:
The net proceeds will be used to advance the clinical development of CT-388, a novel once-weekly dual GLP-1 and GIP receptor modulator, for the treatment of type-2 diabetes and obesity.
Lead Product(s): CT-388
Therapeutic Area: Endocrinology Product Name: CT-388
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering November 17, 2023
Details:
CT-868 is a once-daily subcutaneous injectable, dual GLP-1/GIP receptor agonist being developed as an adjunct to insulin for the treatment of people with type 1 diabetes (T1D) with overweight or obesity.
Lead Product(s): CT-868
Therapeutic Area: Endocrinology Product Name: CT-868
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2023
Details:
CT-996 is a once-daily oral, small molecule GLP-1 receptor agonist being developed for the treatment of obesity and type 2 diabetes (T2D). it was designed to exhibit signaling bias on the GLP-1 receptor, resulting in activation of cAMP.
Lead Product(s): CT-996
Therapeutic Area: Endocrinology Product Name: CT-996
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2023
Details:
The proceeds will be used to strengthen Carmot's portfolio of clinical and preclinical assets designed to modulate gut hormones that are central to energy homeostasis, including CT-388, a dual GLP-1/GIP receptor modulator for obese adults with and without type 2 diabetes.
Lead Product(s): CT-388
Therapeutic Area: Endocrinology Product Name: CT-388
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Deep Track Capital
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Series E Financing May 25, 2023
Details:
The spin-off enables Carmot to focus on clinical-stage candidates CT-388 and CT-868 (dual GLP-1/GIP receptor modulators), additional IND-stage programs including CT-996 (an oral, small molecule GLP-1 receptor agonist) and a long-acting PYY analogue.
Lead Product(s): CT-388
Therapeutic Area: Endocrinology Product Name: CT-388
Highest Development Status: Phase IProduct Type: Peptide
Recipient: Kimia Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Demerger January 05, 2023
Details:
The funding will support the phase 2 studies for CT-388, a dual modulator of the GLP-1 and GIP incretin receptors, phase 1 studies for CT-996, an oral small molecule GLP-1 receptor agonist, and phase 2 studies for CT-868, a first-inclass fully biased GLP-1/GIP modulator.
Lead Product(s): CT-388
Therapeutic Area: Endocrinology Product Name: CT-388
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: The Column Group
Deal Size: $160.0 million Upfront Cash: Undisclosed
Deal Type: Series D Financing July 26, 2022
Details:
FDA recently approved LUMAKRAS for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.
Lead Product(s): Sotorasib
Therapeutic Area: Oncology Product Name: Lumakras
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Amgen Inc
Deal Size: $240.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration June 29, 2021
Details:
CT-388 is a fully biased dual GLP-1 and GIP receptor modulator with a unique pharmacological profile optimized for improved tolerability at the GLP-1 receptor, anticipated to be dosed once-weekly.
Lead Product(s): CT-388
Therapeutic Area: Endocrinology Product Name: CT-388
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
